Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Protein Kinase C (Prkc)

  • Alexandra C. Newton
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101822

Historical Background

Protein kinase C was discovered in the late 1970s by Yasutomi Nishizuka and his team at Kobe University, Japan. They had originally purified a kinase that required only Mg2+ for activity, so they named it protein kinase M (PKM). It soon became apparent to the group that PKM was a proteolytic product of a larger enzyme whose kinase activity needed to be unmasked by cofactors. They named the parent enzyme protein kinase C because a Ca2+-dependent protease cleaved it to release the unregulated kinase moiety they had initially purified. The subsequent identification of diacylglycerol as the key cofactor provided an explanation for how lipid hydrolysis, discovered 25 years earlier to be triggered by stimuli such as acetylcholine, couples to intracellular signaling pathways. But the discovery that shot PKC into the limelight was its specific binding to, and activation by, tumor-promoting phorbol esters, a discovery that was facilitated by the synthesis of relatively...

This is a preview of subscription content, log in to check access.

References

  1. Alfonso SI, Callender JA, Hooli B, Antal CE, Mullin K, Sherman MA, Lesne SE, Leitges M, Newton AC, Tanzi RE, et al. Gain-of-function mutations in protein kinase Calpha (PKCalpha) may promote synaptic defects in Alzheimer’s disease. Sci Signal. 2016;9:ra 47.CrossRefGoogle Scholar
  2. Antal CE, Callender JA, Kornov AP, Taylor SS, Newton AC. Intramolecular C2 domain-mediated autoinhibition of protein kinase CbII. Cell Rep. 2015a. doi:10.1016/j.celrep.2015.07.039.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, et al. Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell. 2015b;160:489–502.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008;27:1932–43.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 2008;283:6300–11.CrossRefGoogle Scholar
  6. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Natl Rev Cancer. 2007;7:281–94.CrossRefGoogle Scholar
  7. Hansra G, Garcia-Paramio P, Prevostel C, Whelan RD, Bornancin F, Parker PJ. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes [In Process Citation]. Biochem J. 1999;342:337–44.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015;163:712–23.CrossRefPubMedGoogle Scholar
  9. Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell. 2010;37:541–50.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Humphries MJ, Ohm AM, Schaack J, Adwan TS, Reyland ME. Tyrosine phosphorylation regulates nuclear translocation of PKCdelta. Oncogene. 2008;27:3045–53.CrossRefPubMedGoogle Scholar
  11. Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27:1919–31.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Leonard TA, Rozycki B, Saidi LF, Hummer G, Hurley JH. Crystal structure and allosteric activation of protein kinase C betaII. Cell. 2011;144:55–66.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Newton AC. Diacylglycerol’s affair with protein kinase C turns 25. Trends Pharmacol Sci. 2004;25:175–7.CrossRefPubMedGoogle Scholar
  14. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–14.CrossRefPubMedGoogle Scholar
  15. Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Natl Rev Mol Cell Biol. 2010;11:103–12.CrossRefGoogle Scholar
  16. Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 2004;384:449–59.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Stempka L, Girod A, Müller H-J, Rincke G, Marks F, Gschwendt M, Bossemeyer D. Phosphorylation of protein kinase Cd (PKCd) at threonine 505 is not a prerequisite for enzymatic activity. J Biol Chem. 1997;272:6805–11.CrossRefPubMedGoogle Scholar
  18. Tobias IS, Kaulich M, Kim PK, Simon N, Jacinto E, Dowdy SF, King CC, Newton AC. Protein kinase Czeta exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation. Biochem J. 2016;473:509–23.CrossRefPubMedGoogle Scholar
  19. Tobias IS, Newton AC. Protein scaffolds control localized protein kinase C zeta activity. J Biol Chem. 2016;291:13809–22.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Trujillo JI, Kiefer JR, Huang W, Thorarensen A, Xing L, Caspers NL, Day JE, Mathis KJ, Kretzmer KK, Reitz BA, et al. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett. 2009;19:908–11.CrossRefPubMedGoogle Scholar
  21. Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA. PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci. 2008;121:2339–49.CrossRefPubMedGoogle Scholar
  22. Violin JD, Zhang J, Tsien RY, Newton AC. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J Cell Biol. 2003;161:899–909.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell. 2015;163:1237–51.CrossRefPubMedGoogle Scholar
  24. Wu-Zhang AX, Newton AC. Protein kinase C pharmacology: refining the toolbox. Biochem J. 2013;452:195–209.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of PharmacologyUniversity of California San DiegoSan DiegoUSA